“In addition to an adaptive immunological reaction to the capsid of AAV, the transgene can elicit both an adaptive and an innate response…Finally, a transgene with a significant number of CpG dinucleotides can activate innate response through toll-like receptor (TLR) molecular pattern receptors [Faust et al., 2013].”
Click here for full article
May 18th, 2018 - Naso et al., 2017, Adeno-Associated Virus (AAV) as a Vector for Gene Therapy, BioDrugs, 31: 317-314.
